The ERBB network: at last, cancer therapy meets systems biology

被引：796

作者：

Yarden, Yosef ^{[1
]}

Pines, Gur ^{[1
]}

机构：

[1] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel

来源：

NATURE REVIEWS CANCER | 2012年 / 12卷 / 08期

基金：

欧洲研究理事会;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; PREVIOUSLY TREATED PATIENTS; NEU DIFFERENTIATION FACTOR; EGF RECEPTOR KINASE; CARCINOMA IN-SITU; HUMAN-TUMOR CELLS; PHASE-II TRIAL;

D O I：

10.1038/nrc3309

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.

引用

页码：553 / 563

页数：11

共 182 条

[1]

EFFICACY OF ANTIBODIES TO EPIDERMAL GROWTH-FACTOR RECEPTOR AGAINST KB CARCINOMA INVITRO AND IN NUDE-MICE [J].